Sona Nanotech

Using Nanotechnology to Transform Diagnostics and Healthcare

Overview

Sona Nanotech Inc. (CSE:SONA,OTCQB:SNANF) is a nanotechnology life science company that has developed two unique gold nanorod products: GeminiTM and OmniTM. These products allow individuals to take control of their health and help fight some of the world’s deadliest diseases. GeminiTM is a CTAB-free gold nanorod product that enables multiplexing of lateral flow diagnostic tests for multiple analytes on just one device that provides accurate results in minutes.

Lateral flow diagnostic testing platforms can confirm the absence or presence of a target analyte or contaminants. The tests are widely used in human health point-of-care testing and have a variety of other applications across numerous industries due to their versatility. Sona Nanotech’s technology offers numerous advantages over current labels when incorporated into lateral flow assays, including multiple distinct colors for simple identification and quantification measurement as well as increasing test performance by improving limits of detection and time to results.

The company has also developed OmniTM; a non-toxic gold nanorod, which is also CTAB-free, that could be used In-vivo (inside cells) for medical applications such as drug delivery, photothermal therapy and cell imaging.

Aside from its gold nanorod products, Sona Nanotech offers additional services that utilize its technology, including conjugation services, lateral flow test development and lateral flow test production. The company also offers a complete end-to-end lateral flow test solution with its partners that includes a lateral flow test reader and a mobile smartphone app that collects and stores results.

Sona Nanotech generates revenue from its products in four ways: reagent sales, contract development services, licenses and royalties and test manufacturing. Through its four revenue channels, Sona Nanotech expects to generate $35.9 million in revenue by 2025. Most of the company’s revenue is generated through its licensing and royalty agreements, where licensees pay an annual or one-time fee per license and royalties are collected each quarter on an on-going basis.

Sona Nanotech continues to develop and apply its proprietary technology to improve existing multiplex diagnostic testing platforms in the market and has partnered with numerous organizations with this in mind. The company has partnered or collaborated with others to advance its technology, reduce overhead costs and expand its distribution network.

Sona Nanotech has a commercial agreement with Expedeon AG (FWB:EXN,ISIN:DE000A1RFM03) for the distribution of the company’s technology and a collaboration agreement with Soma Bioscience for the development of two test kits. Some of the company’s other partners include Romer labs, Operon, Cape Breton University, Bond Digital Health Solutions, OLM Diagnostics and Anteo Technologies.

Sona Nanotech Company Highlights

  • Sona Nanotech has developed two gold nanorod products: GeminiTM and OmniTM.
  • Sona’s CTAB-free GeminiTM is a CTAB-free gold nanorod product that enables multiplexing of lateral flow diagnostic tests for multiple analytes on just one device that provides accurate results in minutes.
  • GeminiTM rods offers numerous advantages over current labels when incorporated into lateral flow assays, including multiple distinct colors for simple identification and quantification measurement as well as increasing test performance by improving limits of detection and time to results
  • OmniTM, a non-toxic gold nanorod, which is also CTAB-free, that could be used In-vivo (inside cells) for medical applications such as drug delivery, photothermal therapy and cell imaging.
  • Sona Nanotech generates revenue through licenses and royalties as well as reagent sales, contract development services and test manufacturing.
  • The company expects to generate $35.9 million in revenue by 2025 through its four revenue channels.
  • Continuous product development is a cornerstone of Sona Nanotech’s business model and has led to numerous partnerships and collaborations.
  • The company has partnerships in place with Expedeon, Romer labs, Soma Bioscience, Bond Digital Health, Cape Breton University, Operon and Anteo Technologies, among others.